NVA237 BID Versus Placebo Twelve-week Efficacy Study
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 432
- Registration Number
- NCT01715298
- Locations
- 🇺🇸
Novartis Investigative Site, Tacoma, Washington, United States
Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control
Phase 4
Withdrawn
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01715311
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
Phase 3
Completed
- Conditions
- Tuberous Sclerosis Complex-associated Refractory Seizures
- Interventions
- Drug: PlaceboDrug: Antiepileptic drug (1 to 3 only)Drug: open label RAD001 (only used for post-extension phase)
- First Posted Date
- 2012-10-25
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 366
- Registration Number
- NCT01713946
- Locations
- 🇺🇸
University of Chicago SC - 2, Chicago, Illinois, United States
🇺🇸Children's Hospital Boston SC, Boston, Massachusetts, United States
🇺🇸Texas Children s Hospital SC, Houston, Texas, United States
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1001
- Registration Number
- NCT01712516
- Locations
- 🇸🇮
Novartis Investigative Site, Golnik, Slovenia
EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes
Terminated
- Conditions
- Fragile-X Syndrome
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 75
- Registration Number
- NCT01711606
- Locations
- 🇩🇪
Novartis Investigative site, Nuremberg, Germany
Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 134
- Registration Number
- NCT01709838
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
NVA237 Versus Placebo 12-week Efficacy Study
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 440
- Registration Number
- NCT01709864
- Locations
- 🇺🇸
Novartis Investigative Site, Waco, Texas, United States
A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Fluticasone/salmeterolDrug: Placebo to QVA149Drug: Placebo to fluticasone/salmeterol
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 744
- Registration Number
- NCT01709903
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei County, Taiwan
Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS
Phase 4
Withdrawn
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Other: individualized patient support programOther: Standard care
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01709812
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT01708174
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh Dept of Oncology, Pittsburgh, Pennsylvania, United States
🇺🇸Dana Farber Cancer Institute SC-7, Boston, Massachusetts, United States
🇬🇧Novartis Investigative Site, Leeds, United Kingdom